MACK-3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis.

Kee-Huat ChuahWan Nur Illyana Wan YusoffPavai SthaneshwarNik Raihan Nik MustaphaSanjiv MahadevaWah-Kheong Chan

Published in: Liver international : official journal of the International Association for the Study of the Liver (2019)

MACK-3 is promising as a non-invasive test for active NASH and fibrotic NASH and may be useful to identify patients who need more aggressive intervention.

Keyphrases

systemic sclerosis
idiopathic pulmonary fibrosis
randomized controlled trial
liver injury
protein kinase
drug induced